A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D-a randomised multicentre international clinical trial.
Jorge B Cannata-AndíaAugusto Díaz-SottolanoPehuén FernándezCarmen Palomo-AntequeraPablo Herrero-PuenteRicardo MouzoNatalia Carrillo-LópezSara PanizoGuillermo H IbañezCarlos A CusumanoCarolina BallarinoVicente Sánchez-PoloJacqueline Pefaur-PennaIrene Maderuelo-RiescoJesús Calviño-VarelaMónica D GómezCarlos Gómez-AlonsoJohn CunninghamManuel Naves-DíazWalter DouthatJosé L Fernández-Martínnull nullPublished in: BMC medicine (2022)
COVID-VIT-D trial was authorised by the Spanish Agency for Medicines and Health products (AEMPS) and registered in European Union Drug Regulating Authorities Clinical Trials (EudraCT 2020-002274-28) and in ClinicalTrials.gov ( NCT04552951 ).
Keyphrases
- clinical trial
- coronavirus disease
- sars cov
- phase ii
- study protocol
- phase iii
- double blind
- open label
- healthcare
- public health
- respiratory syndrome coronavirus
- emergency department
- mental health
- randomized controlled trial
- adverse drug
- risk assessment
- metabolic syndrome
- social media
- insulin resistance
- drug induced
- climate change